Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy

被引:0
作者
Sare Sipal
Zekai Halici
İlhami Kiki
Beyzagul Polat
Abdulmecit Albayrak
Fatih Albayrak
Emre Karakus
Selina Aksak
Berna Ozturk
Cemal Gundogdu
机构
[1] Ataturk University,Department of Pathology, Faculty of Medicine
[2] Ataturk University,Department of Pharmacology, Faculty of Medicine
[3] Ataturk University,Department of Internal Medicine, Division of Hematology, Faculty of Medicine
[4] Ataturk University,Department of Internal Medicine, Division of Gastroenterelogy, Faculty of Medicine
[5] Ataturk University,Department of Histology and Embryology, Faculty of Medicine
来源
Journal of Molecular Histology | 2012年 / 43卷
关键词
Hepatic fibrosis; Olmesartan; Losartan; Valsartan; Stereology; Diabetes; Electron microscopy;
D O I
暂无
中图分类号
学科分类号
摘要
The presence of liver disease in patients with progressively worsening insulin resistance may not be recognized until patients develop manifestations of the metabolic syndrome such as diabetes, hypertension, hyperlipidemia, and vascular disease. It was aimed to investigate whether three angiotensin II type 1 receptor antagonists (ARBs) (olmesartan, losartan, and valsartan) had preventive effect against hepatic fibrosis and this was a common characteristic among ARBs. In current study, 25 adult male rats were used and divided into five groups: the non-diabetic healthy group, alloxan induced diabetic (AID) control group, AID losartan group, AID valsartan group and AID olmesartan group. According to numerical density of hepatocytes, significant difference was found between the non-diabetic healthy group and diabetic control group. All treatments groups were significant when compared to diabetic control group. In diabetic control group it was examined swelling, irregular cristae arrangement in some of mitochondria. It was also determined mitochondria membrane degeneration in some areas of section profiles. In diabetic rats treated with losartan group, there were necrotic hepatocytes. In diabetic rats treated with valsartan group, predominantly, findings were similar to losartan group. In diabetic rats treated with olmesertan group, plates of hepatocytes were quite regular. There were hardly necrotic cells. Not only other organelles such as RER, SER and lysosom but also mitochondrial structures had normal appearance. In the diabetic control group electron microscopy revealed edema in both the cytoplasm and perinuclear area and the nuclear membranes appeared damaged. In conclusion, it was established that the most protective ARB the liver in diabetic rats was olmesartan, followed by losartan.
引用
收藏
页码:723 / 735
页数:12
相关论文
共 272 条
  • [1] Altunkaynak BZ(2012)Effects of diabetes and ovariectomy on rat hippocampus (a biochemical and stereological study) Gynecol Endocrinol 28 228-233
  • [2] Unal D(1986)Estimation of surface area from vertical sections J Microsc 142 259-276
  • [3] Altunkaynak ME(2003)NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis J Clin Invest 112 1383-1394
  • [4] Halici Z(2005)Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats Hepatology 41 1046-1055
  • [5] Kalkan Y(2000)Renin-angiotensin-aldosterone system and myocardial fibrosis Cardiovasc Res 47 1-3
  • [6] Keles ON(2003)Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation Endocr Rev 24 261-271
  • [7] Aksak S(2007)Effects of swimming training at the intensity equivalent to aerobic/anaerobic metabolic transition in alloxan diabetic rats J Diabetes Complicat 21 258-264
  • [8] Selli J(2004)Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types J Comp Neurol 472 449-462
  • [9] Unal B(2006)Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists Vascul Pharmacol 45 154-162
  • [10] Baddeley AJ(1995)The role of vasoactive mediators in portal hypertension Semin Gastrointest Dis 6 140-147